These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 38760269)

  • 41. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers.
    Moncunill G; Aguilar R; Ribes M; Ortega N; Rubio R; Salmerón G; Molina MJ; Vidal M; Barrios D; Mitchell RA; Jiménez A; Castellana C; Hernández-Luis P; Rodó P; Méndez S; Llupià A; Puyol L; Rodrigo Melero N; Carolis C; Mayor A; Izquierdo L; Varela P; Trilla A; Vilella A; Barroso S; Angulo A; Engel P; Tortajada M; García-Basteiro AL; Dobaño C
    EBioMedicine; 2022 Jan; 75():103805. PubMed ID: 35032961
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection by Type and Frequency of Vaccine: A Community-Based Case-Control Study.
    Gim H; Seo H; Chun BC
    J Korean Med Sci; 2024 Jun; 39(21):e174. PubMed ID: 38832478
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
    Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M
    Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
    Tang P; Hasan MR; Chemaitelly H; Yassine HM; Benslimane FM; Al Khatib HA; AlMukdad S; Coyle P; Ayoub HH; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Al Romaihi HE; Butt AA; Al-Thani MH; Al Khal A; Bertollini R; Abu-Raddad LJ
    Nat Med; 2021 Dec; 27(12):2136-2143. PubMed ID: 34728831
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Infections, Hospitalizations, and Deaths Among US Nursing Home Residents With vs Without a SARS-CoV-2 Vaccine Booster.
    McConeghy KW; Bardenheier B; Huang AW; White EM; Feifer RA; Blackman C; Santostefano CM; Lee Y; DeVone F; Halladay CW; Rudolph JL; Zullo AR; Mor V; Gravenstein S
    JAMA Netw Open; 2022 Dec; 5(12):e2245417. PubMed ID: 36477482
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relative Vaccine Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron Variant.
    Butt AA; Talisa VB; Shaikh OS; Omer SB; Mayr FB
    Clin Infect Dis; 2022 Dec; 75(12):2161-2168. PubMed ID: 35511586
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines.
    Kelly JD; Leonard S; Hoggatt KJ; Boscardin WJ; Lum EN; Moss-Vazquez TA; Andino R; Wong JK; Byers A; Bravata DM; Tien PC; Keyhani S
    JAMA; 2022 Oct; 328(14):1427-1437. PubMed ID: 36156706
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar.
    Chemaitelly H; Tang P; Hasan MR; AlMukdad S; Yassine HM; Benslimane FM; Al Khatib HA; Coyle P; Ayoub HH; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Al Romaihi HE; Butt AA; Al-Thani MH; Al Khal A; Bertollini R; Abu-Raddad LJ
    N Engl J Med; 2021 Dec; 385(24):e83. PubMed ID: 34614327
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes.
    Buchan SA; Chung H; Brown KA; Austin PC; Fell DB; Gubbay JB; Nasreen S; Schwartz KL; Sundaram ME; Tadrous M; Wilson K; Wilson SE; Kwong JC
    JAMA Netw Open; 2022 Sep; 5(9):e2232760. PubMed ID: 36136332
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.
    Shrotri M; Krutikov M; Palmer T; Giddings R; Azmi B; Subbarao S; Fuller C; Irwin-Singer A; Davies D; Tut G; Lopez Bernal J; Moss P; Hayward A; Copas A; Shallcross L
    Lancet Infect Dis; 2021 Nov; 21(11):1529-1538. PubMed ID: 34174193
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP.
    Hulme WJ; Horne EMF; Parker EPK; Keogh RH; Williamson EJ; Walker V; Palmer TM; Curtis HJ; Walker AJ; Andrews CD; Mehrkar A; Morley J; MacKenna B; Bacon SCJ; Goldacre B; Hernán MA; Sterne JAC
    BMJ; 2023 Mar; 380():e072808. PubMed ID: 36921925
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022.
    Hall VJ; Insalata F; Foulkes S; Kirwan P; Sparkes D; Atti A; Cole M; de Lacy E; Price L; Corrigan D; Brown CS; Islam J; Charlett A; Hopkins S;
    J Infect; 2024 Jan; 88(1):30-40. PubMed ID: 37926119
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative effectiveness of different primary vaccination courses on mRNA-based booster vaccines against SARs-COV-2 infections: a time-varying cohort analysis using trial emulation in the Virus Watch community cohort.
    Nguyen VG; Yavlinsky A; Beale S; Hoskins S; Byrne TE; Lampos V; Braithwaite I; Fong WLE; Fragaszy E; Geismar C; Kovar J; Navaratnam AMD; Patel P; Shrotri M; Weber S; Hayward AC; Aldridge RW
    Int J Epidemiol; 2023 Apr; 52(2):342-354. PubMed ID: 36655537
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination.
    Durier C; Ninove L; van der Werf S; Lefebvre M; Desaint C; Bauer R; Attia M; Lecompte AS; Lachatre M; Maakaroun-Vermesse Z; Nicolas JF; Verdon R; Kiladjian JJ; Loubet P; Schmidt-Mutter C; Corbin V; Ansart S; Melica G; Resch M; Netzer E; Kherabi Y; Tardieu R; Lelièvre JD; Tartour E; Meyer L; de Lamballerie X; Launay O;
    Infect Dis Now; 2024 Aug; 54(5):104886. PubMed ID: 38494117
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021.
    Thompson MG; Burgess JL; Naleway AL; Tyner HL; Yoon SK; Meece J; Olsho LEW; Caban-Martinez AJ; Fowlkes A; Lutrick K; Kuntz JL; Dunnigan K; Odean MJ; Hegmann KT; Stefanski E; Edwards LJ; Schaefer-Solle N; Grant L; Ellingson K; Groom HC; Zunie T; Thiese MS; Ivacic L; Wesley MG; Lamberte JM; Sun X; Smith ME; Phillips AL; Groover KD; Yoo YM; Gerald J; Brown RT; Herring MK; Joseph G; Beitel S; Morrill TC; Mak J; Rivers P; Harris KM; Hunt DR; Arvay ML; Kutty P; Fry AM; Gaglani M
    MMWR Morb Mortal Wkly Rep; 2021 Apr; 70(13):495-500. PubMed ID: 33793460
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron.
    Wei Y; Jia KM; Zhao S; Hung CT; Mok CKP; Poon PKM; Man Leung EY; Wang MH; Yam CHK; Chow TY; Guo Z; Yeoh EK; Chong KC
    JAMA Netw Open; 2023 Feb; 6(2):e2254777. PubMed ID: 36735253
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel.
    Pilishvili T; Gierke R; Fleming-Dutra KE; Farrar JL; Mohr NM; Talan DA; Krishnadasan A; Harland KK; Smithline HA; Hou PC; Lee LC; Lim SC; Moran GJ; Krebs E; Steele MT; Beiser DG; Faine B; Haran JP; Nandi U; Schrading WA; Chinnock B; Henning DJ; Lovecchio F; Lee J; Barter D; Brackney M; Fridkin SK; Marceaux-Galli K; Lim S; Phipps EC; Dumyati G; Pierce R; Markus TM; Anderson DJ; Debes AK; Lin MY; Mayer J; Kwon JH; Safdar N; Fischer M; Singleton R; Chea N; Magill SS; Verani JR; Schrag SJ;
    N Engl J Med; 2021 Dec; 385(25):e90. PubMed ID: 34551224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.